Epidermal growth factor polymorphism most prevalent in stage II cervical carcinoma
Article Sidebar
Main Article Content
Abstract
Cervical cancer ranks second among female cancers worldwide and is widely associated with human papilloma virus (HPV) infection. However, HPV infection progression is influenced by various host factors. Epidermal growth factor (EGF) is a host factor important for proper epithelial proliferation and development, and may play a role in cervical cancer progression. A functional A61G polymorphism in the EGF gene has been hypothesized to alter EGF concentration in vivo with increasing guanine content associated with greater EGF level. However, a map of A61G polymorphism distribution is not available for any population, including Indonesia. This study aims to determine the distribution of EGF A61G polymorphism among cervical cancer patients at Dr. Hasan Sadikin General Hospital.
Methods
A retrospective cross-sectional study was conducted between July-November 2010. Included were 61 cervical cancer patients of various stages at Dr. Hasan Sadikin hospital, who had previously undergone blood sample collection, DNA isolation and finally genotyping for EGF gene using Illumina BeadXpress®. Chi-square test was used to analyse the data.
Results
The EGF A61G polymorphism was exhibited by 88.5% of patients (as genotypes A/G and G/G). The majority of patients with this polymorphism were of moderate severity (FIGO stage II and III, 42.6% and 38.1% respectively). Patients with the polymorphism but with the lightest severity (FIGO stage I) accounted for 22.2% of the population.
Conclusion
EGF A61G polymorphism affected the majority of cervical cancer patients and that once stratified, the patients showed intermediate severity in terms of their cancerous growth.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
WHO/ICO Information Center on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Indonesia. Barcelona;2010.
Sahiratmadja E, Tobing MDL, Dewayani BM, Hernowo BS, Susanto H. Multiple human papillomavirus infections predominant in squamous cell cervical carcinoma in Bandung. Univ Med 2014;33:58-64.
Chauhan S, Jaggi M, Bell M, Verma M, Kumar D. Epidemiology of human papilloma virus (HPV) in cervical mucosa. Methods Mol Biol 2009;471:439-56. doi: 10.1007/978-1-59745-416-2_22.
zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Nat Cancer Inst 2000;92:690-8.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther 2011;11:295-306.
Narayanan R, Kim HN, Narayanan NK, Nargi D, Narayanan B. Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels. Int J Oncol 2012;40:13-20.
Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005;17:1183-93.
Bag A, Jyala NS, Bag N. Indian studies on genetic polymorphisms and cancer risk. Ind J Cancer 2012;49:144-62.
Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
Li TF, Ren KW, Liu PF. Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol 2012;31:568-74.
Araujo AP, Ribeiro R, Pereira D, Pinto D, Sousa B, Catarino R, et al. Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene. Exp Biol Med 2009;234:241-5.
Kang S, Kim JW, Park NH, Song YS, Park SY, Kang SB, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007;17:492-6.
Araujo AP, Catarino R, Ribeiro R, Pereira D, Pinto D, Medeiros R. Epidermal growth factor genetic variation associated with advanced cervical cancer in younger women. Am J Clin Oncol 2012;35:247-50.
Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 2008;14:3216-22.
Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynecol Obstet 2009;105:107-8.
Dahlan MS. Besar sampel dan cara pengambilan sampel. Jakarta: Salemba Medika;2013.